Enzyme replacement therapy for the mucopolysaccharide storage disorders.
about
The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunctionCNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorderEnzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type miceSialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage diseaseAn overview of Korean patients with mucopolysaccharidosis and collaboration through the Asia Pacific MPS Network.Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment.The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseasesThe first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I.Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product.Current and potential therapeutic strategies for mucopolysaccharidoses.Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase.Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice.Enzyme replacement therapy and extended newborn screening for mucopolysaccharidoses: opinions of treating physicians.
P2860
Q24603159-9324E3B9-88DC-4C9A-8C3F-1517A9F631C6Q28732722-356B3C7C-954F-4460-B1D1-00BCC524E93EQ28749673-2D8AA603-015A-41D5-891A-7EECDD170ECAQ30519560-4C356861-6177-4827-BBC8-107784E3B276Q34426433-4FCD717E-ED3A-497B-AC8B-3F5A77735C92Q34562817-93AB77D4-0CE6-4CA1-9C37-0BEF2447B336Q35145713-30E58716-2FD0-430E-AC39-C292C8862952Q36082084-AD1A4073-A1EA-4E8C-A207-73A493400C4EQ36953167-BE00707D-F5C9-4518-8660-E32B3300554CQ38194635-5649167B-87B6-4C8C-B927-4B616A46B5A7Q38340653-B7B212A4-76D3-46FA-84C3-9DB7B5F20F0CQ41838643-15F1FA68-3624-4FDA-8BD4-6A50B8535B84Q42367666-F713E420-C93B-426D-BC55-45DC74E3533E
P2860
Enzyme replacement therapy for the mucopolysaccharide storage disorders.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Enzyme replacement therapy for the mucopolysaccharide storage disorders.
@ast
Enzyme replacement therapy for the mucopolysaccharide storage disorders.
@en
Enzyme replacement therapy for the mucopolysaccharide storage disorders.
@nl
type
label
Enzyme replacement therapy for the mucopolysaccharide storage disorders.
@ast
Enzyme replacement therapy for the mucopolysaccharide storage disorders.
@en
Enzyme replacement therapy for the mucopolysaccharide storage disorders.
@nl
prefLabel
Enzyme replacement therapy for the mucopolysaccharide storage disorders.
@ast
Enzyme replacement therapy for the mucopolysaccharide storage disorders.
@en
Enzyme replacement therapy for the mucopolysaccharide storage disorders.
@nl
P2860
P1476
Enzyme replacement therapy for the mucopolysaccharide storage disorders.
@en
P2093
Emil D Kakkis
P2860
P304
P356
10.1517/13543784.11.5.675
P407
P577
2002-05-01T00:00:00Z